Information on EC 3.4.19.12 - ubiquitinyl hydrolase 1 and Organism(s) Homo sapiens

for references in articles please use BRENDA:EC3.4.19.12
Word Map on EC 3.4.19.12
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
This record set is specific for:
Homo sapiens


The taxonomic range for the selected organisms is: Homo sapiens

The enzyme appears in selected viruses and cellular organisms

EC NUMBER
COMMENTARY hide
3.4.19.12
-
RECOMMENDED NAME
GeneOntology No.
ubiquitinyl hydrolase 1
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
Thiol-dependent hydrolysis of ester, thioester, amide, peptide and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-residue protein attached to proteins as an intracellular targeting signal)
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of peptide bond
-
-
-
-
CAS REGISTRY NUMBER
COMMENTARY hide
189642-63-5
-
86480-67-3
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
Ac-ALRGG-7-amido-4-trifluoromethylcoumarin
?
show the reaction diagram
-
-
-
?
Ac-LRGG-7-amido-4-trifluoromethylcoumarin
?
show the reaction diagram
-
-
-
?
Ac-RLRGG-7-amido-4-trifluoromethylcoumarin
?
show the reaction diagram
-
-
-
?
activity-based haemagglutinin-tagged ubiquitin + H2O
?
show the reaction diagram
-
-
-
-
?
alpha-Tubulin + H2O
?
show the reaction diagram
-
-
-
-
?
beta-tubulin + H2O
?
show the reaction diagram
-
-
-
-
?
branched di-ubiquitin + H2O
ubiquitin
show the reaction diagram
branched polyubiquitin + H2O
ubiquitin
show the reaction diagram
isopeptide-linked ubiquitin chains
-
?
di-ubiquitin + H2O
ubiquitin
show the reaction diagram
-
recombinant linear substrate, expressed in Escherichia coli
-
-
-
HCF-1 + H2O
?
show the reaction diagram
HCF-1 is the principal Bap1-interacting protein. It is K48- and K63-ubiquitinated. Endogenous HCF-1C is ubiquitinated at lysine-1807 and/or lysine-1808
-
-
?
head-to-tail polyubiquitin + H2O
ubiquitin
show the reaction diagram
-
recombinant substrate from expression in Escherichia coli
-
-
?
hemagglutinin-tagged ubiquitin-vinyl methyl ester + H2O
?
show the reaction diagram
-
-
-
-
?
inhibitor of kappa B-alpha + H2O
?
show the reaction diagram
-
UCHL1 deubiquitinates, thereby resulting in nuclear factor-kappa B inactivation
-
-
?
K48-linked tetraubiquitin + H2O
K48-linked diubiquitin + diubiquitin
show the reaction diagram
-
-
-
-
?
K63-linked polyubiquitin + H2O
K63-linked polyubiquitin + ubiquitin
show the reaction diagram
-
-
-
-
?
monoubiquitin + H2O
?
show the reaction diagram
N2-L-Asp-ubiquitin + H2O
ubiquitin + L-Asp
show the reaction diagram
-
-
-
?
N2-Lys-ubiquitin + H2O
ubiquitin + Lys
show the reaction diagram
-
ubiquitin amide of the alpha amino group of lysine
-
?
N6-(N2-acetyl)Lys-ubiquitin + H2O
ubiquitin + N2-acetyl-Lys
show the reaction diagram
-
ubiquitin amide of the alpha amino group of lysine
-
?
N6-Lys-ubiquitin + H2O
ubiquitin + Lys
show the reaction diagram
Nalpha-(diubiquitin)-[L-Lys] + H2O
?
show the reaction diagram
-
K48 linked diubiquitin
-
-
?
Nalpha-ubiquitin-[MQIFVRPR] + H2O
ubiquitin + MQIFVRPR
show the reaction diagram
-
-
-
-
?
Nedd-8 + H2O
?
show the reaction diagram
-
-
-
-
?
NEDD8-protein + H2O
NEDD8 + protein
show the reaction diagram
enzyme shows dual specificity for ubiquitin-conjugates and NEDD8-conjugates
-
?
Nepsilon-(diubiquitin)-[Nalpha-actyl-L-Lys] + H2O
?
show the reaction diagram
-
K48 linked diubiquitin
-
-
?
polyubiquitin + H2O
ubiquitin
show the reaction diagram
Smad2 + H2O
?
show the reaction diagram
-
weaker association
-
-
?
Smad3 + H2O
?
show the reaction diagram
-
weaker association
-
-
?
Smad7 + H2O
?
show the reaction diagram
-
association with Smad7, which can act as an adaptor able to recruit UCH37 to the type I TGF-beta receptor and reverses Smurf-mediated ubiquitination
-
-
?
spermidine-ubiquitin + H2O
ubiquitine + spermidine
show the reaction diagram
-
-
-
-
?
type I TGF-beta receptor + H2O
?
show the reaction diagram
ubiquitin + H2O
?
show the reaction diagram
-
-
-
-
?
ubiquitin + H2O
monoubiquitin
show the reaction diagram
-
UCH-L1 removes and recycles ubiquitin molecules from degraded proteins
-
-
?
ubiquitin 7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
ubiquitin C-terminal amide + H2O
ubiquitin + NH3
show the reaction diagram
-
-
-
-
?
ubiquitin ethyl ester + H2O
ubiquitin + ethanol
show the reaction diagram
-
-
-
-
?
ubiquitin glycine methyl ester + H2O
ubiquitin + methanol
show the reaction diagram
-
-
-
-
?
ubiquitin thiol ester of dithiothreitol + H2O
ubiquitin + dithiothreitol
show the reaction diagram
-
-
-
-
?
ubiquitin-4-methylcoumarin 7-amide + H2O
ubiquitin + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
ubiquitin-4-methylcoumarine 7-amide + H2O
ubiquitin + 7-amino-4-methylcoumarine
show the reaction diagram
-
-
-
-
?
ubiquitin-7-amido-4-methylcoumarin + H2O
ubiquitin + 7-amino-4-methylcoumarin
show the reaction diagram
ubiquitin-alcohol + H2O
ubiquitin + alcohol
show the reaction diagram
-
-
-
ir
ubiquitin-AMC + H2O
?
show the reaction diagram
-
-
-
-
?
ubiquitin-B domain of staphylococcal protein-A + H2O
ubiquitin + B domain of staphylococcal protein-A
show the reaction diagram
-
and variants thereof, substrate is expressed as alpha-linked C-terminal fusion to ubiquitin
-
-
?
ubiquitin-beta1 domain of streptococcal protein G + H2O
ubiquitin + beta1 domain of streptococcal protein G
show the reaction diagram
-
and variants thereof, substrate is expressed as alpha-linked C-terminal fusion to ubiquitin
-
-
?
ubiquitin-carboxyl extension protein + H2O
ubiquitin + ubiquitin-carboxyl extension protein
show the reaction diagram
-
carboxyl extension protein of 52 amino acids
-
-
ubiquitin-CEP52 + H2O
ubiquitin + CEP52
show the reaction diagram
-
substrate of UCHL1/PGP 9.5, no activity with UCHL3
-
-
?
ubiquitin-CEP80 + H2O
ubiquitin + CEP80
show the reaction diagram
-
substrate of UCHL3 and UCHL1/PGP 9.5
-
-
?
ubiquitin-peptide + H2O
?
show the reaction diagram
ubiquitin-protein + H2O
ubiquitin + protein
show the reaction diagram
ubiquitin-rhodamine110-glycine + H2O
rhodamine110
show the reaction diagram
-
-
-
-
?
ubiquitinyl-7-amido-4-methylcoumarin + H2O
ubiquitin + 7-amino-4-methylcoumarin
show the reaction diagram
mechanistic studies
-
-
?
ubiquitinyl-peptide + H2O
ubiquitin + peptide
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
polyubiquitin + H2O
ubiquitin
show the reaction diagram
type I TGF-beta receptor + H2O
?
show the reaction diagram
Q9Y5K5
UCH37 deubiquitinates and stabilizes type I TGF-beta receptor. Overexpression of UCH37 upregulates TGF-beta-dependent transcription
-
-
?
ubiquitin-CEP52 + H2O
ubiquitin + CEP52
show the reaction diagram
-
substrate of UCHL1/PGP 9.5, no activity with UCHL3
-
-
?
ubiquitin-CEP80 + H2O
ubiquitin + CEP80
show the reaction diagram
-
substrate of UCHL3 and UCHL1/PGP 9.5
-
-
?
ubiquitin-peptide + H2O
?
show the reaction diagram
ubiquitin-protein + H2O
ubiquitin + protein
show the reaction diagram
Q9UK80
important role in regulation of cell growth
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Cu2+
-
0.2 mol per mol of protein, native isozyme ISOT-S
Ni2+
-
0.5 mol per mol of protein, native isozyme ISOT-S
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(3E)-1-(3,4-dichlorobenzyl)-4-methoxy-5-phenyl-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0061 mM
(3E)-1-(3,4-dichlorobenzyl)-5-iodo-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.00094 mM; IC50: 0.016 mM
(3E)-1-(3,4-dichlorobenzyl)-5-methoxy-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0029 mM
(3E)-1-{2-bromo-2-[3-(trifluoromethyl)phenyl]ethyl}-5-chloro-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0095 mM
(3E)-3-[(acetyloxy)imino]-1-(3,4-dichlorobenzyl)-2-oxoindoline-5-carbonitrile
-
IC50: 0.012 mM
(3E)-3-[(acetyloxy)imino]-1-(3,4-dichlorobenzyl)-2-oxoindoline-5-carboxamide
-
IC50: 0.0041 mM
(3E)-3-[(acetyloxy)imino]-1-(3,4-dichlorobenzyl)-2-oxoindoline-5-carboxylic acid
-
IC50: 0.05 mM
(3E)-5-(trifluoromethoxy)-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0034 mM
(3E)-5-(trifluoromethoxy)-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-oxime
-
IC50: 0.078 mM
(3E)-5-bromo-1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.00081 mM
(3E)-5-chloro-1-(2,3-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0027 mM
(3E)-5-chloro-1-(2,4-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0012 mM
(3E)-5-chloro-1-(2,5-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.00088 mM
(3E)-5-chloro-1-(2-chloro-5-fluorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0065 mM
(3E)-5-chloro-1-(2-naphthylmethyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.014 mM
(3E)-5-chloro-1-(2-phenylethyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.019 mM
(3E)-5-chloro-1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0018 mM; IC50: 0.017 mM
(3E)-5-chloro-1-(3,5-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0013 mM
(3E)-5-chloro-1-(3-chloro-4-methoxybenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.021 mM
(3E)-5-chloro-1-(3-methoxybenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.013 mM
(3E)-5-chloro-1-(4-chlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.012 mM
(3E)-5-chloro-1-(4-methoxybenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.052 mM
(3E)-5-chloro-1-[2-(3,4-dichlorophenoxy)ethyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0062 mM
(3E)-5-chloro-1-[2-(3,4-dichlorophenyl)ethyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0013 mM
(3E)-5-chloro-1-[2-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.018 mM
(3E)-5-chloro-1-[2-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-oxime
-
IC50: 0.321 mM
(3E)-5-chloro-1-[3-(3,4-dichlorophenyl)propyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.016 mM
(3E)-5-chloro-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.006 mM; IC50: 0.036 mM
(3E)-5-chloro-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-oxime
-
IC50: 0.114 mM
(3E)-5-chloro-1-[4-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.012 mM
(3E)-5-chloro-1-[4-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-oxime
-
IC50: 0.013 mM
(3E)-5-chloro-1-{1-[2-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0088 mM
(3E)-5-chloro-1-{1-[2-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-oxime
-
IC50: 0.045 mM
(3E)-5-chloro-1-{1-[3-(trichloromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0034 mM
(3E)-5-chloro-1-{1-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-oxime
-
IC50: 0.022 mM
(3E)-5-chloro-1-{2-ethoxy-2-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.095 mM
(3E)-5-chloro-1-{2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.019 mM
(3E)-5-chloro-1-{2-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0041 mM
(3E)-5-chloro-1-{2-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-oxime
-
IC50: 0.08 mM
(3E)-5-chloro-7-methyl-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.012 mM
(3E)-5-fluoro-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0061 mM
(3E)-5-fluoro-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-oxime
-
IC50: 0.043 mM
(3E)-6-chloro-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0058 mM
1-(1,3-benzodioxol-5-ylmethyl)-4-(4-([(4-chlorophenyl)thio]methyl)benzoyl) piperazine
-
slight inhibition of UCH-L1
1-benzyl-3-hydroxy-4-(5-methyl-2-furoyl)-5-(3-pyridinyl)-1,5-dihydro-2H-pyrrol-2-one
-
is a competitive inhibitor of UCH-L3, significantly inhibits hydrolysis activity of UCH-L3 by 83.2%
15-deoxy-DELTA12,14-prostaglandin J2
-
modification of UCH-L1 by cyclopentenone prostaglandins causes unfolding and aggregation. A single thiol group on Cys152 reacts with the alpha,beta-unsaturated carbonyl center in the cyclopentenone ring of prostaglandins, resulting in a covalent adduct, spectral analysis, overview
2-([4-(2-furylmethyl)-5-(2-thienylmethyl)-4H-1,2,4-triazol-3-yl]thio)-N-(2-methoxydibenzo[b,d]furan-3-yl)acetamide
-
-
2-propenal
-
carbonyl modification with 0.1 mM
2-[(5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio]-N-(4-methyl-2-pyridinyl)acetamide
-
-
3-hydroxy-5-(4-methoxyphenyl)-1-(1,3,4-thiadiazol-2-yl)-4-(2-thienylcarbonyl)-1,5-dihydro-2H-pyrrol-2-one
-
significantly inhibits hydrolysis activity of UCH-L3 by 76.5%
3-[4-methyl-5-(([3-(2-thienyl)-1,2,4-oxadiazol-5-yl]methyl)thio)-4H-1,2,4-triazol-3-yl]-1H-indole
-
inhibits hydrolysis activity by 16.2%
4-([benzyl(methyl)amino]sulfonyl)-N-[5-(benzylthio)-1,3,4-thiadiazol-2-yl]benzamide
-
-
4-hydroxy-2-hexenal
-
carbonyl modification in a dose-dependent manner
4-hydroxy-2-nonenal
-
carbonyl modification with 0.01-0.1 mM leads to decreased ubiquitin binding, and both increased insolubility and interactions with proteins over 30 kDa compared with the wild-type
5-(4-fluorophenyl)-3-hydroxy-4-(5-methyl-2-furoyl)-1-(3-pyridinylmethyl)-1,5-dihydro-2H-pyrrol-2-one
-
significantly inhibits hydrolysis activity of UCH-L3 by 76.8%
5-chloro-1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
-
IC50: 0.0018 mM
5-chloro-1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione 3-oxime
-
IC50: 0.012 mM
8-[(1H-benzimidazol-2-ylmethyl)sulfanyl]-2,2-dimethyl-5-(morpholin-4-yl)-1,4-dihydro-2H-pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine
-
-
aldehyde product of fatty acid peroxidation
i.e. HNE; modifies isozyme L1 at physiological concentrations of 0.01-0.1 mM and reduces enzyme activity, excess N-acetyl-L-cysteine protects
-
benzyloxycarbonyl-Val-Ala-Glu(gamma-methoxy) fluoromethylketone
-
co-crystal structure reveals that the inhibitor binds in the active-site cleft, irreversibly modifying the active-site cysteine
dimethyl sulfoxide
-
catalytic activity decreases slightly with increasing dimethyl sulfoxide concentrations. At 2% (v/v) dimethyl sulfoxide, the proteolytic activity of UCH-L3 is reduced by ca. 5% in comparison to dimethyl sulfoxide-free conditions
dipicolinic acid
-
-
DTT
-
erythrocyte isozyme ISOT-S and ISOT-L, inhibition by chelating of Zn2+
EDTA
-
-
EGTA
-
-
epoxysuccinyl-leucylamido-(4-guanidino) butane
-
reduces UCH-L1 mRNA, protein level and activity. Caspase-mediated apoptosis in epoxysuccinyl-leucylamido-(4-guanidino) butane-treated fibroblasts is reversed by transfection with a UCH-L1 plasmid
iodoacetamide
isatin O-acyl oximes
-
reversible and competitive inhibition, inhibitory potency and features of the drivatives, specific inhibition of UCH-L1, poor inhibition of UCH-L3, IC50 values, overview
J series prostaglandins
-
inhibition of the enzyme is involved in disruption of the proteasome pathway and leads to apoptosis
-
LDN 57 444
-
UCH-L1 inhibition leads to a time and concentration-dependent formation of membrane protrusions, accompanied by redistribution of alpha-actinin-4 to the membrane. Expression level of alpha-actinin-4 remains stable, whereas the beta-catenin content increases. Inhibition of UCH-L1 does not induce apoptosis
N,N'-(oxydi-4,1-phenylene)dibenzenesulfonamide
-
slight inhibition of UCH-L1
N,N'-4,4'-biphenyldiylbis(4-ethylbenzenesulfonamide)
-
strong inhibition of UCH-L1
N-(2-[(6,7-dimethoxy-1-isoquinolinyl)methyl]-4,5-dimethoxyphenyl)-4-(2-oxo-1-pyrrolidinyl)benzenesulfonamide
-
slight inhibition of UCH-L1
N-(3,6-dichloro-2-pyridinyl)-N'-([(4,6-diphenyl-2-pyrimidinyl)amino]carbonyl)sulfamide
-
-
N-(4-([(4-ethoxyphenyl)amino]sulfonyl)phenyl)-2-naphthalenesulfonamide
-
slight inhibition of UCH-L1
N-(4-([(4-methylphenyl)amino]sulfonyl)phenyl)-2-phenyl-2-(phenylthio)acetamide
-
slight inhibition of UCH-L1
N-ethylmaleimide
UBPY
N-[2-(4-benzyl-1-piperazinyl)-2-oxoethyl]-N-(3-methylphenyl)benzenesulfonamide
-
slight inhibition of UCH-L1
nitrilo-triacetate
-
-
peptides
-
containing either of the cleavage site sequence found in ubiquitin polymers, but not unrelated peptides
RNAi
-
siRNA
-
ubiquitin
Ubiquitin aldehyde
-
inhibition mechanism
-
ubiquitin vinyl methyl ester
-
a ubiquitin-based suicide substrate, binding structure analysis with wild-type and mutant S18Y enzymes, overview
-
ubiquitin vinylmethyl ester
inhibitor forms a covalent adduct with the active site cysteine of the enzyme
-
ubiquitin vinylsulfone
-
irreversible inhibitor that covalently modifies the active-site cysteines of DUBs
-
ubiquitin-aldehyde
-
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
2-mercaptoethanol
-
active-site thiol is very sensitive to oxidation and requires reductants
4-hydroxy-2-alkenal
-
modification of UCH-L1 promotes direct interactions between UCH-L1 and tubulin
4-hydroxy-2-nonenal
-
modification of UCH-L1 promotes direct interactions between UCH-L1 and tubulin
Adrm1
-
recruits Uch37 to the proteasome. Binds the carboxy-terminal tail of Uch37. Following binding, Adrm1 relieves Uch37 autoinhibition, accelerating the hydrolysis of ubiquitin-7-amido-4-methylcoumarin
-
DTT
-
active-site thiol is very sensitive to oxidation and requires reductants
ethyl 1-[N-(4-methylphenyl)-N-(methylsulfonyl)alanyl]-4-piperidinecarboxylate
-
-
H2O2
-
-
Sodium citrate
activation of the enzymes with increasing salt concentration, reaching a maximum above 0.8 M. Most effective activation in the case of UCH-L3, where 1.1 M sodium citrate enhances catalysis on the synthetic substrate Ac-LRGG-7-amido-4-trifluoromethylcoumarin about 24fold, compared with low-salt conditions. The tetrapeptide substrate Ac-LRGG-7-amido-4-trifluoromethylcoumarin and the pentapeptide substrate containing alanine at position P5, namely Ac-ALRGG-7-amido-4-trifluoromethylcoumarin, both demonstrate a salt effect, but the pentapeptide substrate containing arginine in position P5, Ac-RLRGG-7-amido-4-trifluoromethylcoumarin, does not demonstrate one; activation of the enzymes with increasing salt concentration, reaching a maximum above 0.8 M. The tetrapeptide substrate Ac-LRGG-7-amido-4-trifluoromethylcoumarin and the pentapeptide substrate containing alanine at position P5, namely Ac-ALRGG-7-amido-4-trifluoromethylcoumarin, both demonstrate a salt effect, but the pentapeptide substrate containing arginine in position P5, Ac-RLRGG-7-amido-4-trifluoromethylcoumarin, does not demonstrate one; activation of the enzymes with increasing salt concentration, reaching a maximum above 0.8 M. Weakest activation in the case of IsoT, where there is almost no increase in catalysis compared with low salt conditions. The tetrapeptide substrate Ac-LRGG-7-amido-4-trifluoromethylcoumarin and the pentapeptide substrate containing alanine at position P5, namely Ac-ALRGG-7-amido-4-trifluoromethylcoumarin, both demonstrate a salt effect, but the pentapeptide substrate containing arginine in position P5, Ac-RLRGG-7-amido-4-trifluoromethylcoumarin, does not demonstrate one
TNFalpha
-
inducer
-
tumor necrosis factor-alpha
-
treatment of cultured vascular smooth muscle cells for 24 and 48 hours does not significantly alter UCHL1 mRNA levels, whereas long term treatment (96 hours) significantly increases UCHL1 mRNA levels. Treatment of aortic endothelial cells and aortic smooth muscle cells with tumor necrosis factor-alpha for 24 hours does not significantly alter UCHL1 mRNA levels
-
ubiquitin
20fold enhancement of the cleavage of Ac-LRGG-7-amido-4-trifluoromethylcoumarin by IsoT in the presence of equimolar ubiquitin; iIn the case of OTU-1 full-length ubiquitin does not result in any substantial decrease or increase of the processing of the fluorigenic substrate
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.002
branched dimeric ubiquitin
-
pH 7.2, 37°C
-
0.015
head-to-tail dimeric ubiquitin
-
pH 7.2, 37°C
-
0.000047 - 0.02149
ubiquitin 7-amido-4-methylcoumarin
-
0.0006
ubiquitin ethyl ester
-
isozyme L1
-
0.0000833
ubiquitin-7-amido-4-methylcoumarin
-
-
-
0.00011 - 0.00014
ubiquitin-7-amino-4-methylcoumarin
-
0.000034
ubiquitin-rhodamine110-glycine
-
-
-
0.000035
ubiquitinyl-7-amido-4-methylcoumarin
-
pH 7.5, 25°C
additional information
additional information
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0011 - 33.67
ubiquitin 7-amido-4-methylcoumarin
-
0.0794 - 0.196
ubiquitin-7-amino-4-methylcoumarin
-
4.72
ubiquitin-rhodamine110-glycine
-
-
-
0.001
ubiquitinyl-7-amido-4-methylcoumarin
-
pH 7.5, 25°C
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000104 - 7410
ubiquitin 7-amido-4-methylcoumarin
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00014 - 0.00019
ubiquitin
0.000001
Ubiquitin aldehyde
-
below, pH 7.5, 25°C, inhibition kinectis
-
additional information
additional information
-
inhibition kinetics of isatin O-acyl oximes, overview
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0061
(3E)-1-(3,4-dichlorobenzyl)-4-methoxy-5-phenyl-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0061 mM
0.00094 - 0.016
(3E)-1-(3,4-dichlorobenzyl)-5-iodo-1H-indole-2,3-dione 3-(O-acetyloxime)
0.0029
(3E)-1-(3,4-dichlorobenzyl)-5-methoxy-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0029 mM
0.0095
(3E)-1-{2-bromo-2-[3-(trifluoromethyl)phenyl]ethyl}-5-chloro-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0095 mM
0.012
(3E)-3-[(acetyloxy)imino]-1-(3,4-dichlorobenzyl)-2-oxoindoline-5-carbonitrile
Homo sapiens
-
IC50: 0.012 mM
0.0041
(3E)-3-[(acetyloxy)imino]-1-(3,4-dichlorobenzyl)-2-oxoindoline-5-carboxamide
Homo sapiens
-
IC50: 0.0041 mM
0.05
(3E)-3-[(acetyloxy)imino]-1-(3,4-dichlorobenzyl)-2-oxoindoline-5-carboxylic acid
Homo sapiens
-
IC50: 0.05 mM
0.0034
(3E)-5-(trifluoromethoxy)-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0034 mM
0.078
(3E)-5-(trifluoromethoxy)-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-oxime
Homo sapiens
-
IC50: 0.078 mM
0.00081
(3E)-5-bromo-1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.00081 mM
0.0027
(3E)-5-chloro-1-(2,3-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0027 mM
0.0012
(3E)-5-chloro-1-(2,4-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0012 mM
0.00088
(3E)-5-chloro-1-(2,5-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.00088 mM
0.0065
(3E)-5-chloro-1-(2-chloro-5-fluorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0065 mM
0.014
(3E)-5-chloro-1-(2-naphthylmethyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.014 mM
0.019
(3E)-5-chloro-1-(2-phenylethyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.019 mM
0.0018 - 0.017
(3E)-5-chloro-1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
0.0013
(3E)-5-chloro-1-(3,5-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0013 mM
0.021
(3E)-5-chloro-1-(3-chloro-4-methoxybenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.021 mM
0.013
(3E)-5-chloro-1-(3-methoxybenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.013 mM
0.012
(3E)-5-chloro-1-(4-chlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.012 mM
0.052
(3E)-5-chloro-1-(4-methoxybenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.052 mM
0.0062
(3E)-5-chloro-1-[2-(3,4-dichlorophenoxy)ethyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0062 mM
0.0013
(3E)-5-chloro-1-[2-(3,4-dichlorophenyl)ethyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0013 mM
0.018
(3E)-5-chloro-1-[2-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.018 mM
0.321
(3E)-5-chloro-1-[2-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-oxime
Homo sapiens
-
IC50: 0.321 mM
0.016
(3E)-5-chloro-1-[3-(3,4-dichlorophenyl)propyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.016 mM
0.006 - 0.036
(3E)-5-chloro-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
0.114
(3E)-5-chloro-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-oxime
Homo sapiens
-
IC50: 0.114 mM
0.012
(3E)-5-chloro-1-[4-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.012 mM
0.013
(3E)-5-chloro-1-[4-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-oxime
Homo sapiens
-
IC50: 0.013 mM
0.0088
(3E)-5-chloro-1-{1-[2-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0088 mM
0.045
(3E)-5-chloro-1-{1-[2-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-oxime
Homo sapiens
-
IC50: 0.045 mM
0.0034
(3E)-5-chloro-1-{1-[3-(trichloromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0034 mM
0.022
(3E)-5-chloro-1-{1-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-oxime
Homo sapiens
-
IC50: 0.022 mM
0.095
(3E)-5-chloro-1-{2-ethoxy-2-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.095 mM
0.019
(3E)-5-chloro-1-{2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.019 mM
0.0041
(3E)-5-chloro-1-{2-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0041 mM
0.08
(3E)-5-chloro-1-{2-[3-(trifluoromethyl)phenyl]ethyl}-1H-indole-2,3-dione 3-oxime
Homo sapiens
-
IC50: 0.08 mM
0.012
(3E)-5-chloro-7-methyl-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.012 mM
0.0061
(3E)-5-fluoro-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0061 mM
0.043
(3E)-5-fluoro-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-oxime
Homo sapiens
-
IC50: 0.043 mM
0.0058
(3E)-6-chloro-1-[3-(trifluoromethyl)benzyl]-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0058 mM
0.103
1-benzyl-3-hydroxy-4-(5-methyl-2-furoyl)-5-(3-pyridinyl)-1,5-dihydro-2H-pyrrol-2-one
Homo sapiens
-
-
0.154
3-hydroxy-5-(4-methoxyphenyl)-1-(1,3,4-thiadiazol-2-yl)-4-(2-thienylcarbonyl)-1,5-dihydro-2H-pyrrol-2-one
Homo sapiens
-
-
0.123
5-(4-fluorophenyl)-3-hydroxy-4-(5-methyl-2-furoyl)-1-(3-pyridinylmethyl)-1,5-dihydro-2H-pyrrol-2-one
Homo sapiens
-
-
0.0018
5-chloro-1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione 3-(O-acetyloxime)
Homo sapiens
-
IC50: 0.0018 mM
0.012
5-chloro-1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione 3-oxime
Homo sapiens
-
IC50: 0.012 mM
0.015
N,N'-4,4'-biphenyldiylbis(4-ethylbenzenesulfonamide)
Homo sapiens
-
-
0.00074
ubiquitin
Homo sapiens
-
-
0.1
additional information
Homo sapiens
-
IC50 above 0.1 mM: (3E)-5-chloro-1-(pyridin-3-ylmethyl)-1H-indole-2,3-dione 3-(O-acetyloxime), (3E)-5-chloro-1-(pyridin-4-ylmethyl)-1H-indole-2,3-dione 3-(O-acetyloxime), 4-({(3E)-3-[(acetyloxy)imino]-5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl}methyl)benzoi
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
30
-
purified recombinant isozyme L1, substrate ubiquitin ethyl ester; UCH-L1, ubiquitin ethyl ester as substrate
110
-
purified recombinant isozyme L3, substrate ubiquitin ethyl ester; UCH-L3, ubiquitin ethyl ester as substrate
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.2 - 8.3
-
broad optimum
7.2
-
assay at
7.4
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
6 - 9
-
analysis of pH dependence of the reaction, overview
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
25
-
assay at
37
-
assay at
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
-
analysis of temperature dependence of the reaction, overview
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
mRNA and protein expression, expressed in endothelial cells in atherosclerotic lesions from human carotid arteries
Manually annotated by BRENDA team
-
mRNA and protein expression
Manually annotated by BRENDA team
-
UCH-L3 mRNA level is significantly upregulated and UHCL1 mRNA level also show a non-significant increase in breast cancer tissue compared to adjacent normal breast tissue. Both UCH-L1 and UCH-L3 mRNA levels are significantly higher in high histological grade tumors than in low histological grade tumors. UCH-L1 mRNA level in tumors is approximately 10 times higher than that of UCH-L3
Manually annotated by BRENDA team
-
UCH-L1 is highly expressed
Manually annotated by BRENDA team
human cervical carcinoma cell line
Manually annotated by BRENDA team
-
UCHL3 and UCH37 are upregulated in the majority of tumor tissues compared to the adjacent normal tissues. UCH-L1 activity is lower in a significant proportion of the tumors but to a less extent in advanced tumors
Manually annotated by BRENDA team
-
; down-regulation of UCHL-1 mRNA and protein in dementia with Lewy bodies, either in pure forms not associated with Alzheimer disease, and in common forms, with accompanying Alzheimer disease changes, but not in Parkinson disease. UCHL-3 expression reduced in Parkinson disease and dementia with Lewy bodies
Manually annotated by BRENDA team
-
prefrontal. UCH L1 is 1.1-1.2fold decreased in alcoholics
Manually annotated by BRENDA team
-
in accordance with the relatively low UCH-L1 activity in tumor biopsies, UCH-L1 is detected only in one out of eight cervical carcinoma lines
Manually annotated by BRENDA team
-
lymph node metastasis, increased expression
Manually annotated by BRENDA team
accumulated upon growth stimulation of starved human fibroblasts
Manually annotated by BRENDA team
-
non-small cell lung cancer cell line
Manually annotated by BRENDA team
-
isoform UCH-L1 does not partition to the membrane in the cultured cell lines tested
Manually annotated by BRENDA team
-
UCHL1 expression is low, which is well correlated with its promoter methylation status
Manually annotated by BRENDA team
-
UCHL1 expression is low, which is well correlated with its promoter methylation status
Manually annotated by BRENDA team
-
a bronchial epithelial cell line, the cells show increased UCH-L1 expression, overview
Manually annotated by BRENDA team
-
only UCH-L3 is clearly identified in primary keratinocytes. UCH-L1 and UCH-L3 activity is upregulated following HPV E6/E7 immortalization of keratinocytes
Manually annotated by BRENDA team
-
different cell lines
Manually annotated by BRENDA team
-
a B lymphoblastoid cell line
Manually annotated by BRENDA team
-
present in patients with sporadic Parkinson´s disease
Manually annotated by BRENDA team
-
-
Manually annotated by BRENDA team
-
; UCHL-1 mRNA and protein expressions reduced in Parkinson disease
Manually annotated by BRENDA team
-
lung cancer cell line; non-small cell lung cancer cell line
Manually annotated by BRENDA team
-
isoform UCH-L1 does not partition to the membrane in the cultured cell lines tested
Manually annotated by BRENDA team
-
; down regulation of UCHL1 is detected immediately after oxygen-glucose deprivation treatment and its expression is subsequently restored and increased 6 h after oxygen-glucose deprivation treatment as well as during reoxygenation. A lower level of UCHL1 is detected only in apoptotic cells with severe loss of mitochondrial membrane potential. Down-regulation of endogenous UCHL1 by antisense cDNA in mouse N2a neuroblastoma cells increased the cell’s sensitivity to oxygen-glucose deprivation. This down-regulation of endogenous UCHL1 leads to the accumulation of p27, suggesting that UCHL1 is an essential gene to maintain cell homeostasis under normal growth and oxidative stress conditions
Manually annotated by BRENDA team
-
UCHL1 expression is low, which is well correlated with its promoter methylation status
Manually annotated by BRENDA team
-
expresses UCH-L1 and expression correlates with the differentiation status. In the cortex of normal biopsies, UCH-L1 is predominantly expressed in distal tubules, macula densa, and nerve fibres. A subset of human glomerulopathies associated with podocyte foot process effacement (membranous nephropathy, SLE class V, FSGS) de novo express UCH-L1 in podocyte cell bodies, nuclei, and processes
Manually annotated by BRENDA team
expression analysis of UCHL! in the renal cell carcinoma system, profiling, overview
Manually annotated by BRENDA team
-
photoreceptor cells, bipolar cells, and amacrine cells are devoid of staining while the dendrites and axons of both the horizontal cells and the ganglion cells stain strongly
Manually annotated by BRENDA team
-
human prostate cell line
Manually annotated by BRENDA team
-
a bronchial epithelial cell line, the cells show increased UCH-L1 expression, overview
Manually annotated by BRENDA team
-
a neuroblastoma cell line
Manually annotated by BRENDA team
-
level of UCH-L1 mRNA is significantly reduced in fibroblasts of patients affected with lysosomal storage disorders
Manually annotated by BRENDA team
-
UCHL1 expression is low, which is well correlated with its promoter methylation status
Manually annotated by BRENDA team
-
spermatogonia in humans can be subdivided into three types, overview
Manually annotated by BRENDA team
-
UCHL-1 protein reduced in cases with Lewy body pathology
Manually annotated by BRENDA team
-
isozyme L3
Manually annotated by BRENDA team
human osteosarcoma cell line
Manually annotated by BRENDA team
-
UCH37 activity is up-regulated in cervical carcinoma biopsies as well as cell lines, while UCH-L1 activity is lower in cervical carcinomas
Manually annotated by BRENDA team
-
mRNA and protein expression, expressed in vascular smooth muscle cells in atherosclerotic lesions from human carotid arteries
Manually annotated by BRENDA team
human fibroblast cell line
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
undifferentiated podocytes exhibit strong UCH-L1 expression at the cell membrane along leading edges
-
Manually annotated by BRENDA team
-
membrane associated form UCH-L1M, C-terminal farnesylation promotes the association of UCH-L1 with the membrane
Manually annotated by BRENDA team
-
associated to
Manually annotated by BRENDA team
-
the membrane-associated UCH-L1M form is associated with the plasma membrane of oocytes, C-terminal farnesylation promotes the association of UCH-L1 with the membrane
Manually annotated by BRENDA team
additional information
PDB
SCOP
CATH
ORGANISM
UNIPROT
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
25000
-
immunoblot analysis
25902
-
x * 25902, UCH-L1, mass spectrometry
28900
-
x * 28900, SDS-PAGE
110000
-
analytical ultracentrifugation
130000
x * 130000, SDS-PAGE
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
monomer
additional information
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
lipoprotein
-
C-terminal farnesylation promotes the association of UCH-L1 with membranes. Inhibition of UCH-L1 farnesylation by farnesyltransferase inhibitor FTI-277
ubiquitination
-
monoubiquitination is a posttranslational modification of UCH-L1 that controls the function of UCH-L1. It may occur reversibly to a lysine residue near the active site, probably K157, of UCH-L1. This modification restricts enzyme activity by preventing binding to the ubiquitinated targets, and permanent mono-ubiquitination, as mimicked by a ubiquitin-UCH-L1 fusion, inhibits UCH-L1 in its capacity to increase free ubiquitin levels. However, the lifetime of this modification on UCH-L1 is regulated by auto-deubiquitination
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
at 2.4 A resolution, x-ray crystallography. Overall fold resembles that of other ubiquitin hydrolases, including UCHL3. Geometry of the catalytic residues in the active site of UCH-L1 is distorted in such a way that the hydrolytic activity appears to be impossible without substrate induced conformational rearrangements; purified recombinant wild-type and mutant GST-tagged enzymes, 35 mg/ml protein in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM DTT, crystallization at room temperature, X-ray diffraction structure determination and analysis at 2.6 A resolution, molecular modeling, structure-function relationship
-
hanging drop vapour diffusion method, 1.45 A resolution crystal structure of human UCH-L3 in complex with the inhibitor ubiquitin vinylmethyl ester
purified recombinant UCH37 catalytic domain, i.e. UCH37N, selenomethionine-substituted UCH37N, and of mutant C88A, sitting-drop vapor diffusion method, 14 mg/ml protein in 25 mM Tris-HCl, pH 7.5, 1 mM DTT, 20°C, versus a reservoir solution containing 22% PEG 4000, 0.2 M MgCl2, 0.1 M Tris-HCl, pH 8.5, and 3.5% xylitol, microseeding, X-ray diffraction structure determination and analysis at 2.2 A resolution
-
purified recombinant wild-type UCH-L1 and the Parkinson disease-associated variant of the enzyme, mutant S18Y, bound to a ubiquitin-based suicide substrate, ubiquitin vinyl methyl ester, hanging drop vapour diffusion method, 25 mg/ml enzyme-UbVMe complex in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 10 mM DTT, are mixed with 2.4 M ammonium sulfate and 0.1 M bicine, pH 9.0, 2 months, X-ray diffraction structure determination and analysis at 2.4-2.85 A resolution, molecular replacement
-
UCH-L3, crystal structure at 1.8 A resolution
-
X-ray structure of UCHL1 co-crystallized with a peptide-based fluoromethylketone inhibitor, benzyloxycarbonyl-Val-Ala-Glu(gamma-methoxy) fluoromethylketone (Z-VAE(OMe)-FMK (VAEFMK)), at 2.35 A resolution is reported
-
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
52
-
reversible denaturation of wild-type isozymes L1 and L3, and of L1 mutants C90S, H161D, H161K, H161Y, thermodynamics; thermodynamic of denaturation, enthalpy, entropy, Gibbs energy
OXIDATION STABILITY
ORGANISM
UNIPROT
LITERATURE
active-site thiol is very sensitive to oxidation and requires reductants
-
35003
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-60°C
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
affinity purified; affinity purified
-
by anion exchange chromatography and gel filtration
-
by gel filtration; recombinant wild-type and mutant GST-tagged enzymes from Escherichia coli by glutathione affinity chromatography and gel filtration
-
isozyme ISOT-S from erythrocytes; partial, recombinant wild-type and mutant isozymes ISOT-S and ISOT-L from Escherichia coli
-
on Ni-NTA column
-
on Ni-NTA resin
-
purification of GST-tagged UCH-L1 by gel filtration
-
recombinant
recombinant GST-tagged enzyme from Escherichia coli
-
recombinant GST-tagged UCH-L1 from Escherichia coli strain Rosetta BL21(DE3) by glutathione affinity chromatography
-
recombinant GST-tagged wild-type UCHL1 and mutant S18Y from Escherichia coli strain BL21(Rosetta) by glutathione affinity chromatography, cleavage of the tag, and gel filtration
-